Literature DB >> 23065505

Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.

Leonor Senent1, Leonor Arenillas, Elisa Luño, Juan C Ruiz, Guillermo Sanz, Lourdes Florensa.   

Abstract

The reproducibility of the World Health Organization 2008 classification for myelodysplastic syndromes is uncertain and its assessment was the major aim of this study. The different peripheral blood and bone marrow variables required for an adequate morphological classification were blindly evaluated by four cytomorphologists in samples from 50 patients with myelodysplastic syndromes. The degree of agreement among observers was calculated using intraclass correlation coefficient and the generalized kappa statistic for multiple raters. The degree of agreement for the percentages of blasts in bone marrow and peripheral blood, ring sideroblasts in bone marrow, and erythroid, granulocytic and megakaryocytic dysplastic cells was strong (P<0.001 in all instances). After stratifying the percentages according to the categories required for the assignment of World Health Organization subtypes, the degree of agreement was not statistically significant for cases with 5-9% blasts in bone marrow (P=0.07), 0.1-1% blasts in peripheral blood (P=0.47), or percentage of erythroid dysplastic cells (P=0.49). Finally, the interobserver concordance for World Health Organization-defined subtypes showed a moderate overall agreement (P<0.001), the reproducibility being lower for cases with refractory anemia with excess of blasts type 1 (P=0.05) and refractory anemia with ring sideroblasts (P=0.09). In conclusion, the reproducibility of the World Health Organization 2008 classification for myelodysplastic syndromes is acceptable but the defining criteria for blast cells and features of erythroid dysplasia need to be refined.

Entities:  

Mesh:

Year:  2012        PMID: 23065505      PMCID: PMC3659988          DOI: 10.3324/haematol.2012.071449

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  28 in total

1.  Myelodysplastic syndromes: prognostic significance of multilineage dysplasia in patients with refractory anemia or refractory anemia with ringed sideroblasts.

Authors:  Scott M Dunkley; Arumugam Manoharan; Yiu Lam Kwan
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

2.  Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary.

Authors:  John M Bennett; Richard D Brunning; James W Vardiman
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

3.  Understanding interobserver agreement: the kappa statistic.

Authors:  Anthony J Viera; Joanne M Garrett
Journal:  Fam Med       Date:  2005-05       Impact factor: 1.756

4.  Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia.

Authors:  A Matsuda; I Jinnai; F Yagasaki; S Kusumoto; M Minamihisamatsu; S Honda; I Murohashi; M Bessho; K Hirashima
Journal:  Leukemia       Date:  1998-04       Impact factor: 11.528

5.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

6.  Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution.

Authors:  T Nösslinger; R Reisner; E Koller; H Grüner; H Tüchler; H Nowotny; E Pittermann; M Pfeilstöcker
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

7.  Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients.

Authors:  U Germing; N Gattermann; C Strupp; M Aivado; C Aul
Journal:  Leuk Res       Date:  2000-12       Impact factor: 3.156

8.  Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group.

Authors:  P Greenberg; J Anderson; T de Witte; E Estey; P Fenaux; P Gupta; T Hamblin; E Hellstrom-Lindberg; A List; G Mufti; R Neuwirtova; K Ohyashiki; D Oscier; G Sanz; M Sanz; C Willman
Journal:  J Clin Oncol       Date:  2000-10-01       Impact factor: 44.544

9.  The WHO classification of MDS does make a difference.

Authors:  Robert B Howe; Anna Porwit-MacDonald; Robert Wanat; Ramin Tehranchi; Eva Hellström-Lindberg
Journal:  Blood       Date:  2003-12-18       Impact factor: 22.113

10.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

View more
  24 in total

1.  Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).

Authors:  M G Della Porta; H Tuechler; L Malcovati; J Schanz; G Sanz; G Garcia-Manero; F Solé; J M Bennett; D Bowen; P Fenaux; F Dreyfus; H Kantarjian; A Kuendgen; A Levis; J Cermak; C Fonatsch; M M Le Beau; M L Slovak; O Krieger; M Luebbert; J Maciejewski; S M M Magalhaes; Y Miyazaki; M Pfeilstöcker; M A Sekeres; W R Sperr; R Stauder; S Tauro; P Valent; T Vallespi; A A van de Loosdrecht; U Germing; D Haase; P L Greenberg; M Cazzola
Journal:  Leukemia       Date:  2015-02-27       Impact factor: 11.528

2.  Inter-observer agreement in myelodysplastic syndromes.

Authors:  Fernando Ramos; Silvia Fernández-Ferrero
Journal:  Haematologica       Date:  2013-07       Impact factor: 9.941

3.  Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.

Authors:  Eric J Duncavage; Geoffrey L Uy; Allegra A Petti; Christopher A Miller; Yi-Shan Lee; Bevan Tandon; Feng Gao; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Meagan A Jacoby; Amanda F Cashen; Lukas D Wartman; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley; John S Welch
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

4.  Morphological classification of the myelodysplastic syndromes: how much more education of diagnosticians is necessary?

Authors:  John M Bennett
Journal:  Haematologica       Date:  2013-04       Impact factor: 9.941

Review 5.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 6.  Genetics of progression from MDS to secondary leukemia.

Authors:  Andrew J Menssen; Matthew J Walter
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

7.  Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.

Authors:  M G Della Porta; E Travaglino; E Boveri; M Ponzoni; L Malcovati; E Papaemmanuil; G M Rigolin; C Pascutto; G Croci; U Gianelli; R Milani; I Ambaglio; C Elena; M Ubezio; M C Da Via'; E Bono; D Pietra; F Quaglia; R Bastia; V Ferretti; A Cuneo; E Morra; P J Campbell; A Orazi; R Invernizzi; M Cazzola
Journal:  Leukemia       Date:  2014-05-20       Impact factor: 11.528

8.  Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.

Authors:  Sa A Wang; Keyur P Patel; Olga Pozdnyakova; Jie Peng; Zhuang Zuo; Paola Dal Cin; David P Steensma; Robert P Hasserjian
Journal:  Mod Pathol       Date:  2016-07-15       Impact factor: 7.842

9.  Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.

Authors:  Luca Malcovati; Elli Papaemmanuil; Ilaria Ambaglio; Chiara Elena; Anna Gallì; Matteo G Della Porta; Erica Travaglino; Daniela Pietra; Cristiana Pascutto; Marta Ubezio; Elisa Bono; Matteo C Da Vià; Angela Brisci; Francesca Bruno; Laura Cremonesi; Maurizio Ferrari; Emanuela Boveri; Rosangela Invernizzi; Peter J Campbell; Mario Cazzola
Journal:  Blood       Date:  2014-06-26       Impact factor: 22.113

Review 10.  The genetic basis of myelodysplasia and its clinical relevance.

Authors:  Mario Cazzola; Matteo G Della Porta; Luca Malcovati
Journal:  Blood       Date:  2013-10-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.